Reconstituted HDL in Acute Coronary Syndromes

Cardiovascular Therapeutics

Volumn 30, Issue 2, 2012, Pages

  Chenevard, Rémy ^a   Hürlimann, David ^a   Spieker, Lukas ^a   Béchir, Markus ^a   Enseleit, Frank ^a   Hermann, Matthias ^a   Flammer, Andreas J ^a   Sudano, Isabella ^a   Corti, Roberto ^a   Lüscher, Thomas F ^a   Noll, Georg ^a   Ruschitzka, Frank ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Acute coronary syndromes; Endothelial function; Reconstituted HDL

Indexed keywords

ACETYLCHOLINE; ALBUMIN; C REACTIVE PROTEIN; CARDIOVASCULAR AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITROPRUSSIDE SODIUM; RECOMBINANT PROTEIN; RECONSTITUTED HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD FLOW; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VEIN OCCLUSION PLETHYSMOGRAPHY;

ACETYLCHOLINE; ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; FIBRINOLYTIC AGENTS; HEMODYNAMICS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; NITROPRUSSIDE; OMEGA-N-METHYLARGININE; OXIDATIVE STRESS; PLETHYSMOGRAPHY; VASCULITIS; VASODILATOR AGENTS;

EID: 84858248832     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00221.x     Document Type: Article

References (40)

1. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
2. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001;21:13-27.
3. Pajkrt D, Doran J, Koster F, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996;184:1601-1608.
4. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001;285:1711-1718.
5. Schwartz GG. High-density lipoprotein cholesterol as a risk factor and target of therapy after acute coronary syndrome. Am J Cardiol 2009;104(10 Suppl):46E-51E.
6. Loscalzo J. Nitric oxide and vascular disease. N Engl J Med 1995;333:251-253.
7. Levkau B, Hermann S, Theilmeier G, et al. High-density lipoprotein stimulates myocardial perfusion in vivo. Circulation 2004;110:3355-3359.
8. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002;105:1399-1402.
9. Nanjee MN, Doran JE, Lerch PG, Miller NE. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol 1999;19:979-989.
10. Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 2000;275:11278-11283.
11. Tardif JC, Gregoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA 2007;297:1675-1682.
12. Fichtlscherer S, Zeiher AM. Endothelial dysfunction in patients with acute coronary syndrome. Herz 1999;24:534-543.
13. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: Further evidence for the existence of the "vulnerable" patient. Circulation 2004;110:1926-1932.
14. Lloyd-Jones DM, Camargo CA, Jr., Lapuerta P, Giugliano RP, O'Donnell CJ. Electrocardiographic and clinical predictors of acute myocardial infarction in patients with unstable angina pectoris. Am J Cardiol 1998;81:1182-1186.
15. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2002;40:1366-1374.
16. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-Elevation myocardial infarction. J Am Coll Cardiol 2004;44:671-719.
17. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995;25:918-923.
18. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995;91:1314-1319.
19. Turchetti V, Boschi L, Donati G, et al. Endothelium and hemorheology. Clin Hemorheol Microcirc 2004;30:289-295.
20. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: A three-vessel intravascular ultrasound study. Circulation 2002;106:804-808.
21. Nissen SE. Rationale for a postintervention continuum of care: Insights from intravascular ultrasound. Am J Cardiol 2000;86:12H-17H.
22. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003;107:2944-2948.
23. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000-1006.
24. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998;97:716-720.
25. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
26. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003;107:1123-1128.
27. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
28. Klinkhardt U, Graff J, Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther 2002;71:176-185.
29. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003;290:2292-2300.
30. Shaw JA, Bobik A, Murphy A, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 2008;103:1084-1091.
31. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-2122.
32. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-1316.
33. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-1630.
34. Hermann F, Enseleit F, Spieker LE, et al. Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia. Thromb Res 2009;123:460-465.
35. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995;346:467-471.
36. Reilly MP, Tall AR. HDL proteomics: Pot of gold or Pandora's box? J Clin Invest 2007;117:595-598.
37. Ansell BJ, Fonarow GC, Navab M, Fogelman AM. Modifying the anti-inflammatory effects of high-density lipoprotein. Curr Atheroscler Rep 2007;9:57-63.
38. Nofer JR, Van Der Giet M, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004;113:569-581.
39. Faxon DP, Gibbons RJ, Chronos NA, Gurbel PA, Sheehan F. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: The results of the HALT-MI study. J Am Coll Cardiol 2002;40:1199-1204.
40. Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003;108:1176-1183.